W. Michael Flanagan, the Chief Scientific Officer of $RNA, sold 20,000 shares of the company on 06-11-2025 for an estimated $657,694. We received data on the trade from a recent SEC filing. This was a sale of approximately 20.0% of their shares of this class of stock. Following this trade, they now own 80,195 shares of this class of $RNA stock.
$RNA Insider Trading Activity
$RNA insiders have traded $RNA stock on the open market 33 times in the past 6 months. Of those trades, 0 have been purchases and 33 have been sales.
Here’s a breakdown of recent trading of $RNA stock by insiders over the last 6 months:
- SARAH BOYCE (President and CEO) has made 0 purchases and 4 sales selling 73,792 shares for an estimated $2,317,238.
- W. MICHAEL FLANAGAN (Chief Scientific Officer) has made 0 purchases and 6 sales selling 70,194 shares for an estimated $2,204,521.
- TERESA MCCARTHY (Chief Human Resources Officer) has made 0 purchases and 5 sales selling 46,888 shares for an estimated $1,521,991.
- KATHLEEN P. GALLAGHER (Chief Program Officer) has made 0 purchases and 10 sales selling 38,786 shares for an estimated $1,184,280.
- MICHAEL F MACLEAN (Chief Financial Officer) has made 0 purchases and 4 sales selling 22,373 shares for an estimated $704,601.
- STEVEN GEORGE HUGHES (Chief Medical Officer) has made 0 purchases and 3 sales selling 13,525 shares for an estimated $410,347.
- ARTHUR A LEVIN sold 1,872 shares for an estimated $53,536
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$RNA Hedge Fund Activity
We have seen 121 institutional investors add shares of $RNA stock to their portfolio, and 152 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- JANUS HENDERSON GROUP PLC added 4,373,686 shares (+62.0%) to their portfolio in Q1 2025, for an estimated $129,111,210
- WELLINGTON MANAGEMENT GROUP LLP added 1,578,459 shares (+19.5%) to their portfolio in Q1 2025, for an estimated $46,596,109
- BANK OF AMERICA CORP /DE/ added 1,395,900 shares (+781.6%) to their portfolio in Q1 2025, for an estimated $41,206,968
- FMR LLC removed 894,542 shares (-5.4%) from their portfolio in Q1 2025, for an estimated $26,406,879
- BOXER CAPITAL MANAGEMENT, LLC removed 862,388 shares (-49.9%) from their portfolio in Q1 2025, for an estimated $25,457,693
- RTW INVESTMENTS, LP added 814,056 shares (+10.3%) to their portfolio in Q1 2025, for an estimated $24,030,933
- T. ROWE PRICE INVESTMENT MANAGEMENT, INC. added 771,158 shares (+inf%) to their portfolio in Q1 2025, for an estimated $22,764,584
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$RNA Analyst Ratings
Wall Street analysts have issued reports on $RNA in the last several months. We have seen 2 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- H.C. Wainwright issued a "Buy" rating on 06/09/2025
- Scotiabank issued a "Outperform" rating on 03/07/2025
To track analyst ratings and price targets for $RNA, check out Quiver Quantitative's $RNA forecast page.
This article is not financial advice. See Quiver Quantitative's disclaimers for more information.
